Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Taki who wrote (148177)	6/14/2006 9:19:20 AM
From: Taki	Respond to of 150070

HTDS.006.Nice news out.Spin off.Another one of a possible good mover in the months to come.Keep an eye on. (COMTEX) B: Hard To Treat Diseases, Incorporated Announces: Spin-Off of Ca it Sciences, Inc. ( CCNMatthews ) B: Hard To Treat Diseases, Incorporated Announces: Spin-Off of Cavit Sciences, I c. ( CCNMatthews ) DELRAY BEACH, FLORIDA, Jun 14, 2006 (CCNMatthews via COMTEX) -- Hard To Treat Diseases, Incorporated (HTTD) (Pink Sheets:HTDS) announces that the Company's Board of Directors voted to spin-off its wholly-owned subsidiary, Cavit Sciences, Inc., to HTTD shareholders of record on June 13, 2006. HTTD had previously assigned certain of its patent application rights and related assets to Cavit Sciences, Inc. ("Cavit"), a corporation formed as a wholly-owned subsidiary of HTTD. Cavit shares were issued to HTTD as consideration for the assets acquired by Cavit. HTTD will distribute the Cavit shares as a stock dividend to the HTTD shareholders of record as of June 13, 2006. HTTD expects to pay the stock dividend on or about September 30, 2006. Cautionary Note Regarding Forward-Looking Statements The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this news release may contain or constitute forward-looking statements. These forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions of the Private Securities Litigation Act of 1995, Hard to Treat Diseases, Inc. provides the following cautionary statement identifying important factors which, among others, could cause the actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions. SOURCE: Hard To Treat Diseases, Incorporated Hard to Treat Diseases, Incorporated Colm J. King CEO (561) 278-7856 www.htdsotc.com Copyright (C) 2006 CCNMatthews. All rights reserved. * end of story *